Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors
NCT ID: NCT03243643
Last Updated: 2017-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
80 participants
INTERVENTIONAL
2017-08-08
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
NCT02977364
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
NCT04477057
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT06598735
A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors
NCT05378178
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HS-1024+apatinib
For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.
For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease).
HS-10241
HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Apatinib
Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HS-10241
HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Apatinib
Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed.；For part 2 (Expansion part) c-met immunohistochemistry (IHC) positive（IHC++ or IHC+++）and with at least one measurable disease according to RECIST 1.1.
3. No difficulty that may hamper compliance and/or absorption of the tested product (swallowing difficulty, chronic gastrointestinal disease like diarrhea and intestinal obstruction )
4. ECOG (Eastern Cooperative Oncology Group) performance status of 0～1.
5. Life expectancy of at least 3 months.
6. Adequate organ function:（No blood transfusion or hematopoietic stimulating factor within 14days of screening stage）：
7. Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:：Absolute neutrophil count (ANC) ≥1500/μL
8. Platelet count ≥90000/μL,，Hemoglobin ≥9.0 g/dL
9. Acceptable liver function defined below:：Total bilirubin ≤ 1.5 times upper limit of normal range (ULN)
10. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN; however, ≤5 times ULN in a subject who has liver metastases.
11. Acceptable renal function defined below:：Serum creatinine ≤1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥60 mL/minutes.
12. Acceptable cardiac function defined below:： left ventricular ejection fraction，LVEF≥50% ；normal ECG，QTc male\<450ms，female\<470ms
13. Recovered from toxicities of prior anti-cancer treatment (NCI-CTCAE 4.03≤ grade 1, except alopecia); Proper period of wash out of previous treatment (at least 5 half-life wash out), e.g. No nitrosoureas or mitomycin within 6 weeks，no cytotoxic drugs, monoclonal antibodies, radiation therapy, or surgery within 4 weeks and no endocrine therapy or tyrosine kinase inhibitors (TKIs) within 2 weeks before first dose of the tested product.
14. Non-surgical sterilization or post-menopause female must agree to use effective means of contraception (IUD , medication or condom ) during and 8 weeks after the clinical trial.Human Chorionic Gonadotropin ( HCG ) serum test must be negative tested 7 days before the first dose of tested product and not being in the lactation period. For male subjects whose female partners have childbearing potential must be surgical sterilization or agree to use effective means of contraception during and 120 days after the clinical trial.
15. Tumor tissue sample available or agree to provide biopsies for testing.
16. Volunteer to participate in the clinical trial, understand the procedure of trial and approved informed consent obtained before entering the trial.
Exclusion Criteria
2. Participation in other clinical trial or the last dose of the other trail was taken within 4 weeks.
3. Other anti-cancer treatment might be received during the trial leading to pause of the trial.
4. Tumor infiltration of the vessel, tumor cavity or necrosis with risk of hemorrhage.
5. Central nervous system (CNS) metastases or meningeal metastases or primary nervous system tumor untreated by surgery or radiotherapy.
6. Patients with clinical symptoms of ascites or pleural effusion, need therapeutic puncture and drainage.
7. Uncontrolled chronic systematic complications (such as chronic pulmonary , hepatic, renal or cardiac diseases).
8. Grade II myocardial ischemia or myocardial infarction or uncontrolled arrhythmia. Cardiac dysfunction with New York Heart Association (NYHA) Class III or IV.
9. Hypertension and unable to be controlled within normal level following treatment of two anti-hypertension agents (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg).
10. Urine protein≥ ++，or 24 hour urine protein≥1.0 g；
11. Patients with or previous with clinically significant hemorrhage within 3 months, with hemorrhage risk or being in anticoagulant and fibrinolytic treatment like gastrointestinal bleeding , hemorrhagic ulcers, baseline defecate occult blood positive and above or vasculitis. Abnormal coagulant function such as INR(international normalized ratio)\>1.5 or PT （Prothrombin Time）\>ULN+4 seconds）.
12. Arterial or venous thromboembolism events within 6 months，like cerebral vascular accident (transient ischemic attack, cerebral hemorrhage or cerebral infarction) or deep venous thrombosis and pulmonary embolism.
13. Active infection needed for treatment.
14. HIV,HBV (Hepatitis B Virus), HCV (Hepatitis C Virus) positive（HBV：HBsAg positive with hepatic function abnormality and HBV-DNA≧104 copy/mL，HCV：HCV-RNA positive with hepatic function abnormality）needed for antivirus treatment（only for Part 1）.
15. History of mental or neurological disorders.
16. Psychiatric drug abuse history or addiction history
17. Unable to complete the trial or withdraw in the middle of the trial due to conditions like psychological state, family relationship, social or geographical factors or with concomitant treatment or abnormal laboratory examinations judging by the investigator.
18. Concomitant diseases ( uncontrolled hypertension , severe diabetes and thyroid disease ) deemed by the investigator to be likely to interfere with the subjects safety or leads to discontinuation from the trial.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital, Sichuan University
Chendu, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS-10241-I-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.